Abstract
Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented
Keywords: Active targeting, cancer therapy, nanocarriers, passive targeting, stealth, inflammation, nucleic acid, Tumour vasculature, epithelium, endothelium
Current Drug Discovery Technologies
Title: Passive and Active Tumour Targeting with Nanocarriers
Volume: 8 Issue: 3
Author(s): Samuli Hirsjarvi, Catherine Passirani and Jean-Pierre Benoit
Affiliation:
Keywords: Active targeting, cancer therapy, nanocarriers, passive targeting, stealth, inflammation, nucleic acid, Tumour vasculature, epithelium, endothelium
Abstract: Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented
Export Options
About this article
Cite this article as:
Hirsjarvi Samuli, Passirani Catherine and Benoit Jean-Pierre, Passive and Active Tumour Targeting with Nanocarriers, Current Drug Discovery Technologies 2011; 8 (3) . https://dx.doi.org/10.2174/157016311796798991
DOI https://dx.doi.org/10.2174/157016311796798991 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Hemichannels in Cerebral Ischemia
Current Molecular Medicine VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Therapeutic Targeting of Apoptotic Pathways in Cancer
Current Drug Targets A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Emerging Treatment Strategies
Current Pharmaceutical Biotechnology Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry High Throughput Screening for Colorectal Cancer Specific Compounds
Combinatorial Chemistry & High Throughput Screening Editorial: Smart Drug Delivery Systems (Part 1)
Current Drug Targets Apoptotic Signaling Pathways as a Target for the Treatment of Liver Diseases
Mini-Reviews in Medicinal Chemistry The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery